eligibility_summary
Include: Advanced cHL (ICD-10 C81.x), stage IIB–IV, systemic therapy–naïve, received first-line A+AVD or ABVD from 7/1/2017–12/31/2020 and completed 6 cycles, ≥2 years retrospective data and ≥2 years follow-up after treatment. Exclude: prior/concurrent malignancy (except excised CIS or basal/squamous skin), concurrent study participation, or prior ECHELON-1 participants.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study compares first-line A+AVD (brentuximab vedotin + doxorubicin + vinblastine + dacarbazine) vs ABVD (doxorubicin + bleomycin + vinblastine + dacarbazine) in advanced classical Hodgkin lymphoma via retrospective chart review. Brentuximab vedotin: antibody-drug conjugate (anti-CD30 mAb linked to MMAE), binds CD30 on Reed-Sternberg cells, internalizes and releases MMAE to disrupt microtubules and induce apoptosis (can also trigger immune effector functions). Doxorubicin: anthracycline, DNA intercalation, topoisomerase II inhibition, ROS generation. Vinblastine: vinca alkaloid, inhibits tubulin polymerization. Dacarbazine: triazene alkylating agent, DNA methylation. Bleomycin: glycopeptide, DNA strand breaks. Targets: CD30+ tumor cells, microtubules, topoisomerase II/DNA replication, DNA damage pathways.